Perrigo Announces Agreement to Divest Infant Formula Business to MeridianMade

Perrigo agreed to sell its Infant Formula business to MeridianMade for total consideration of up to $175 million: $40 million cash at closing and up to $135 million tied to performance milestones through 2030. Perrigo expects the divestiture to simplify its portfolio, enhance its margin profile, eliminate significant expected future capital expenditures and better align reported results with Core Perrigo.

Analysis

The strategic value is less the headline consideration than whether Perrigo removes future capital demands and operating complexity without leaving stranded costs. If the business carried disproportionate investment needs, exiting it could improve cash conversion and the quality of the remaining earnings mix; if shared overhead persists or the divested unit contributed meaningful earnings, reported margins may improve more slowly than management implies. The $40 million closing payment is the certain component; the larger earnout is conditional and should not be valued as cash until milestones and their achievability are clear.

For infant nutrition, transfer to a dedicated contract-manufacturing platform could preserve production continuity while changing who bears future investment and operating risk. That limits the case for assuming a near-term industry supply shock, but execution, regulatory compliance, and customer retention remain the key checks. Larger established formula producers could benefit at the margin if the transition disrupts supply, though the announcement alone does not support that trade.

Near term, PRGO may receive a modest simplification narrative uplift. Over 1–3 months, the market needs pro forma revenue/earnings contribution, stranded-cost detail, expected capex avoided, closing conditions, and earnout milestones to assess whether the disposal is accretive. Over 6–18 months, test the thesis against continuing-operations margins and cash conversion. The contrarian risk is that investors capitalize the full $175 million headline while only a fraction is guaranteed; the upside case is underappreciated if avoided investment and overhead are substantial. No valuation or earnings data here supports a confident directional position.

Key Decisions for Investors

• Treat the announcement as a watch item, not a standalone buy signal. Before adding PRGO, seek the divested unit’s revenue and operating contribution, expected stranded costs, capex avoided, and expected net proceeds.
• If PRGO sells off on lost revenue, consider a measured long only after management quantifies a credible improvement in continuing-business margins or cash conversion; the thesis is falsified if subsequent guidance fails to show those benefits or restructuring costs absorb them.
• Do not underwrite the contingent amount at face value. Track closing conditions and the performance milestones through 2030; a lower realized earnout would weaken the headline-value case but not necessarily the simplification thesis.
• Monitor the buyer’s transition execution and customer/supply continuity. Evidence of production disruption could create a temporary opportunity for established infant-formula competitors, but avoid positioning on that scenario without independent supply or customer evidence.